11 Best Genomics Stocks to Buy According to Hedge Funds

Page 2 of 10

9. Verve Therapeutics, Inc. (NASDAQ:VERV)

Number of Hedge Fund Holders: 30

Revenue growth (YoY): 174.98%

Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion.

Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc. (NASDAQ:VERV)’s  30-day average share price as of June 16, 2025.

Single-dose gene-editing therapies for atherosclerotic cardiovascular disease are being developed by Verve Therapeutics, Inc. (NASDAQ:VERV), including their flagship program VERVE-102, which targets PCSK9. The medication, which is currently in Phase 1b and has been granted FDA Fast Track designation, has the potential to transform care for patients suffering from heterozygous familial hypercholesterolemia and early coronary artery disease.

According to Lilly, Verve Therapeutics, Inc. (NASDAQ:VERV)’s platform strengthens its cardiometabolic pipeline. Sekar Kathiresan, CEO of Verve, stressed the company’s goal of moving from chronic to one-time care. Insiders of the firm who own 17.8% of the company have decided to tender. It is one of the Best Genomics Stocks. 

Page 2 of 10